• In April 2026, Elevance Health reported first-quarter 2026 results showing revenue of US$50.18 billion versus US$48.89 billion a year earlier, alongside lower net income and EPS, reaffirmed full-year 2026 diluted EPS guidance of at least US$19.85, declared a US$1.72 second-quarter dividend, and continued share repurchases under its long-running buyback program.
• While revenue growth coincided with pressure on profitability, Elevance Health’s guidance incorporating the CMS matter and its ongoing capital returns program give investors clearer visibility into how management is balancing earnings, regulation and shareholder payouts.
• Next, we will examine how lower quarterly EPS alongside reaffirmed full-year guidance could reshape Elevance Health’s margin recovery and growth narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Elevance Health Investment Narrative Recap

To own Elevance Health, you need to believe it can manage rising medical costs and regulatory scrutiny while steadily improving margins through technology, value-based care and diversified services. The latest quarter’s revenue growth alongside weaker EPS highlights that cost and reimbursement risks remain central. Reaffirmed 2026 EPS guidance and ongoing capital returns suggest the company is not signaling a material near term change to its core margin recovery catalyst or to its biggest risk around elevated medical cost trends.

The first quarter 2026 buyback update is particularly relevant here: Elevance repurchased 3.7 million shares for US$1,100 million, even as quarterly EPS declined. For shareholders focused on margin recovery and earnings stability, this continued commitment to reducing the share count can help offset earnings pressure per share, but it also sharpens the question of how sustainable such capital returns are if cost pressures in ACA and Medicaid persist or intensify.

Yet, beneath the reaffirmed guidance, investors should be aware that elevated medical cost trends in government plans could still...

Elevance Health's narrative projects $230.4 billion revenue and $7.4 billion earnings by 2028. This requires 6.8% yearly revenue growth and about a $2.0 billion earnings increase from $5.4 billion today.

Uncover how Elevance Health's forecasts yield a $387.85 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming revenue around US$204.7 billion and earnings near US$6.4 billion by 2029, and your view on elevated medical costs and regulatory uncertainty might shift again after this earnings surprise.

Explore 10 other fair value estimates on Elevance Health - why the stock might be worth 18% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Elevance Health research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elevance Health's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.